Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Cancer-associated thrombosis. Intervention: Extended anticoagulation.

Q: What does this research mean for the field?

Optimal extended anticoagulation in cancer-associated thrombosis requires continuous, individualized reassessment of thrombotic versus bleeding risks rather than relying solely on reduced-dose regimens or static treatment durations. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Marcello Di Nisio; Tzu‐Fei Wang

doi:10.1093/ehjcvp/pvag054

July 20, 2026European Heart Journal - Cardiovascular PharmacotherapyOpen Access

Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis

View Full Paper

Ask AI

Bookmark

Share

Graphical abstract published by European Heart Journal - Cardiovascular Pharmacotherapy — Graphical abstract · Published by European Heart Journal - Cardiovascular Pharmacotherapy · CC BY

Key Points

Examine the remaining clinical uncertainties regarding patient selection and treatment duration for extended anticoagulation in cancer-associated thrombosis following the API-CAT trial.
Analyzed clinical trial outcomes from the API-CAT study comparing reduced-dose apixaban (2.5 mg twice daily) with full-dose apixaban (5 mg twice daily) beyond 6 months.
Evaluated prospective decision-making data from investigators choosing post-intervention therapy, analyzed via exploratory multiple correspondence analysis.
In API-CAT, clinically relevant bleeding occurred in 12.1% of patients on reduced-dose apixaban versus 15.6% on full-dose apixaban over 12 months.
Investigators elected to continue anticoagulation in 86.4% of patients and discontinued therapy in 13.6%, with choices weakly correlated with measured clinical variables.
Historical data demonstrate venous thromboembolism recurrence rates of 14.6 events per 100 person-years within 3 months of discontinuation, reaching 28.3% at 1 year and 35% at 5 years.

Structured PICO

P

Population

Patients with cancer-associated thrombosis considering extended anticoagulation

I

Intervention

Extended anticoagulation (direct oral anticoagulants)

Implication

Extended anticoagulation in cancer-associated thrombosis remains a therapeutic grey zone requiring dynamic, individualized reassessment rather than default continuation.

Abstract

[Figure: see text]

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Nisio et al. (2026) conducted an editorial in Cancer-associated thrombosis. Extended anticoagulation was evaluated.

synapsesocial.com/papers/6ad0fc2515427f6a8403ff20 https://doi.org/10.1093/ehjcvp/pvag054

View Full Paper

Ask AI

Bookmark

Share

Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Beyond API-CAT: the remaining challenges of extended anticoagulation for cancer-associated thrombosis

Key Points

Structured PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from European Heart Journal - Cardiovascular Pharmacotherapy

Keep reading

More related papers

More from European Heart Journal - Cardiovascular Pharmacotherapy